Gerrit Weimann
Ingelheim Am Rhein, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Effect of nerandomilast on survival in patients with pulmonary fibrosis.
Journal: The European respiratory journal
Published: February 13, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.
Journal: Annals of the rheumatic diseases
Published: December 23, 2025
Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
Journal: The New England journal of medicine
Published: May 19, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON).
Journal: BMC pulmonary medicine
Published: October 24, 2024
A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial.
Journal: American journal of physiology. Heart and circulatory physiology
Published: January 12, 2024
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 08, 2023
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.
Journal: Respiratory research
Published: May 06, 2022
BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN).
Journal: The European respiratory journal
Published: July 02, 2021
Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT).
Journal: Clinical drug investigation
Published: September 22, 2018
Last Updated: 09/26/2026